gastroenterology
Hepatology

Vedolizumab disappoints in trial for primary sclerosing cholangitis

Hopes for a drug that blocks lymphocyte trafficking into bile ducts to halt progression of primary sclerosing cholangitis have been dashed in a multicentre trial led by Victorian gastroenterologists. The selective α4β7 integrin antibody vedolizumab has been postulated to be of benefit in primary sclerosing cholangitis (PSC) because its healing effect in Crohn’s disease suggested ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic